Franco Vigile is a Canadian entrepreneur, founder, and biotechnology executive focused on building companies that advance innovation, improve human health, and create meaningful real-world impact.
He is the Co-Founder and Chief Executive Officer of N-Zyme Biomedical, a clinical-stage biotechnology company developing the world’s first pepsin inhibitor for reflux disease through a novel drug repurposing strategy. Under his leadership, the company has advanced a growing intellectual property portfolio across major global markets and is progressing toward Phase 2 clinical development.
Prior to N-Zyme, Franco founded HaluGen Life Sciences, a pioneering genetic screening technology platform focused on personalized psychedelic risk assessment, which was later acquired in a multimillion-dollar transaction by Entheon Biomedical, a publicly traded biotechnology company.
He is also the founder of GENNCO Holdings, a boutique advisory and investment firm that has supported numerous public and private financings, strategic initiatives, and early-stage growth companies across the health technology, biotechnology, and capital markets sectors.
With more than a decade of experience spanning entrepreneurship, biotechnology, commercialization strategy, corporate finance, and business development, Franco is recognized for bridging visionary thinking with disciplined execution. His work is driven by a strong belief that innovation should not only create enterprise value, but also meaningfully elevate and improve people’s lives.
Beyond business, Franco is passionate about personal growth, spirituality, and empowering others to pursue purposeful and meaningful lives.